MYLAN NV's gross profit margin for the fourth quarter of its fiscal year 2014 has decreased when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MYLAN NV has very weak liquidity. Currently, the Quick Ratio is 0.47 which clearly shows a lack of ability to cover short-term cash needs. The liquidity decreased from the same period a year ago, despite already having weak liquidity to begin with. This would indicate deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has increased by 10.67% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY14||Q4 FY13|
|Net Sales ($mil)||2082.7||1808.53|
|Net Income ($mil)||189.2||180.23|
|Balance Sheet||Q4 FY14||Q4 FY13|
|Cash & Equiv. ($mil)||225.5||447.8|
|Total Assets ($mil)||15886.6||15236.34|
|Total Debt ($mil)||5732.8||8026.26|
|Profitability||Q4 FY14||Q4 FY13|
|Gross Profit Margin||47.92||53.41|
|Return on Assets||5.85||4.09|
|Return on Equity||28.54||21.2|
|Debt||Q4 FY14||Q4 FY13|
|Share Data||Q4 FY14||Q4 FY13|
|Shares outstanding (mil)||374.16||371.6|
|Div / share||0.0||0.0|
|Book value / share||8.7||7.92|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||3155754.0||4355658.0|
BUY. The current P/E ratio indicates a discount compared to an average of 33.05 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 19.98. To use another comparison, its price-to-book ratio of 6.65 indicates a significant premium versus the S&P 500 average of 2.82 and a significant discount versus the industry average of 8.78. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.
|MYL 24.74||Peers 33.05||MYL NA||Peers 35.95|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
MYL is trading at a significant discount to its peers.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|MYL 12.91||Peers 17.70||MYL 0.15||Peers 0.97|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.
MYL is trading at a discount to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
MYL trades at a significant discount to its peers.
|MYL 6.65||Peers 8.78||MYL 48.10||Peers 37.32|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MYL is trading at a discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
MYL is expected to have an earnings growth rate that significantly exceeds its peers.
|MYL 2.81||Peers 7.08||MYL 11.73||Peers 8.36|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MYL is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
MYL has a sales growth rate that significantly exceeds its peers.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV